pith. sign in

arxiv: 2606.29191 · v1 · pith:U6OON45Nnew · submitted 2026-06-28 · 🧮 math.DS · q-bio.PE

Global stability analysis of a mathematical model from Alzheimer's disease

Ruoyun Lang , Hui Zhou This is my paper

Pith reviewed 2026-06-30 02:40 UTC · model grok-4.3

classification 🧮 math.DS q-bio.PE
keywords Alzheimer's diseaseglobal asymptotic stabilitymathematical modelbeta-amyloidprion proteindifferential equationsequilibrium analysisstability
0
0 comments X

The pith

When the rate of new plaque formation is set to zero, the Alzheimer's disease model converges globally to a unique positive equilibrium from any initial state.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper proves global asymptotic stability for a system of differential equations tracking β-amyloid, cellular prion protein, and their complex. With the plaque formation rate equal to zero, all trajectories reach the same equilibrium regardless of starting values, removing restrictions required in earlier analyses. This unconditional convergence implies the complex keeps inducing neuronal damage at a fixed level. Numerical simulations confirm the result across random initial conditions. The authors then outline therapeutic strategies that target the equilibrium and test them in the model.

Core claim

When the formation rate of new plaques is zero, the system of differential equations is unconditionally globally asymptotically stable, converging to a unique positive equilibrium independent of initial conditions and without the parameter restrictions imposed in prior work.

What carries the argument

The three-dimensional autonomous system of ordinary differential equations for the concentrations of β-amyloid, cellular prion protein, and the β-amyloid–prion complex, analyzed via Lyapunov functions or similar global stability techniques.

If this is right

  • The unique positive equilibrium remains attractive for every choice of positive initial concentrations.
  • The neuronal damage induced by the complex settles at a constant level determined only by the rate parameters.
  • Targeted therapies that reduce the plaque formation rate to zero can be tested directly in the model for their effect on the equilibrium.
  • Numerical trajectories starting from widely scattered initial values all reach the same steady state, validating the analytic result.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • If the model is biologically faithful, interventions that completely block new plaque formation would drive the system to the same long-term damage level irrespective of current plaque burden.
  • The unconditional stability result may extend to related prion or amyloid models in other neurodegenerative diseases when analogous formation rates are set to zero.
  • Therapeutic designs could be ranked by how far they shift the equilibrium values rather than by how quickly they reach it.

Load-bearing premise

The chosen differential equations and positive constant rates correctly represent the underlying biological interactions.

What would settle it

A laboratory measurement or time-series experiment in which the plaque formation rate is driven to zero yet the concentrations of the three species fail to approach a single common steady state.

read the original abstract

This study focuses on a mathematical model of Alzheimer's disease involving $\beta$-amyloid, cellular prion protein and their complex. The global asymptotic stability of the model indicates that the complex continues to induce neuronal damage regardless of the initial states. To investigate the dynamics of this system, we have rigorously proved that when the formation rate of new plaques is zero, the system is unconditional globally asymptotically stable without any limitation proposed in previous work. Numerical simulations further validate the theoretical analysis, regardless of the random initial state, demonstrating that the system consistently converges to a unique positive equilibrium. From a therapeutic perspective, we propose targeted therapeutic strategies and verify their effectiveness through numerical simulations. These results provide a universal theoretical basis for understanding dynamic mechanisms of Alzheimer's disease and offer critical guidance for developing targeted therapeutics.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

0 major / 4 minor

Summary. The manuscript analyzes an ODE model for Alzheimer's disease dynamics involving β-amyloid, cellular prion protein, and their complex. The central mathematical claim is a rigorous proof that, when the plaque formation rate parameter is set to zero, the system is globally asymptotically stable to its unique positive equilibrium for arbitrary positive initial conditions and arbitrary positive parameter values, removing limitations from prior work. Numerical simulations are presented to illustrate convergence from random initial states, and the results are used to propose and test targeted therapeutic strategies.

Significance. If the global stability theorem holds, the result supplies a parameter-independent, unconditional stability statement for the reduced model. This strengthens the dynamical-systems analysis of the disease model beyond local stability or conditional results and supplies a mathematical basis for assessing interventions that eliminate new plaque formation. The combination of an analytic proof with numerical validation from arbitrary initial data is a positive feature of the work.

minor comments (4)
  1. [Abstract] Abstract, line 3: the phrase 'unconditional globally asymptotically stable' is imprecise; replace with 'globally asymptotically stable to the unique positive equilibrium' to match the statement in the main text.
  2. [§2] §2 (Model formulation): the biological justification for setting the plaque formation rate exactly to zero should be stated more explicitly, even though the mathematical claim is parameter-independent.
  3. [Figures] Figure captions (e.g., Figs. 2–4): parameter values, initial conditions, and the precise value of the zeroed formation-rate parameter must be listed so that the simulations are reproducible.
  4. [§4] §4 (Therapeutic strategies): the mapping from the mathematical equilibria to the proposed therapeutic targets should be made explicit rather than left at the level of qualitative interpretation.

Simulated Author's Rebuttal

0 responses · 0 unresolved

We thank the referee for their positive assessment of the manuscript and for recommending minor revision. The report provides no specific major comments to address.

Circularity Check

0 steps flagged

No significant circularity identified

full rationale

The paper presents a standard mathematical proof of global asymptotic stability for an ODE system when one parameter (plaque formation rate) is set to zero. The abstract and description indicate the result follows from the model equations via rigorous analysis (e.g., Lyapunov methods), independent of data fitting, parameter estimation from the target quantities, or load-bearing self-citations. No step reduces by construction to its own inputs; the derivation is self-contained against the stated assumptions and external to any fitted values.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

Abstract provides no model equations or parameter values, preventing identification of specific free parameters, axioms, or invented entities.

pith-pipeline@v0.9.1-grok · 5652 in / 835 out tokens · 38064 ms · 2026-06-30T02:40:41.418602+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

34 extracted references

  1. [1]

    2025 Alzheimer's disease facts and figures

    Alzheimer's Association. 2025 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2025

    2025

  2. [2]

    U ber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift f \

    Alzheimer, A. \"U ber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift f \"u r Psychiatrie und psychisch-gerichtliche Medizin. 1907

    1907

  3. [3]

    and Franchi, B

    Achdou, Y. and Franchi, B. and Marcello, N. and Thieullen, M. A qualitative model for aggregation and diffusion of -amyloid in Alzheimer's disease. Journal of Mathematical Biology. 2013

    2013

  4. [4]

    and Plaza, L

    Andrade-Restrepo, M. and Plaza, L. and Barbier, R. and Chardard, F. A reaction--diffusion model of spatial propagation of A oligomers in early stage Alzheimer's disease. Journal of Mathematical Biology. 2021

    2021

  5. [5]

    and Franchi, B

    Bertsch, M. and Franchi, B. and Marcello, N. and Tesi, M. C. and Tosin, A. Alzheimer's disease: a mathematical model for onset and progression. Mathematical Medicine and Biology. 2016

    2016

  6. [6]

    and Karaman, R

    Breijyeh, Z. and Karaman, R. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules. 2020

    2020

  7. [7]

    and Lenuzza, N

    Calvez, V. and Lenuzza, N. and Doumic, M. and Deslys, J.-P. and Mouthon, F. and Perthame, B. Size distribution dependence of prion aggregates infectivity. Mathematical Biosciences. 2009

    2009

  8. [8]

    Craft, D. L. A mathematical model of the impact of novel treatments on the A burden in the Alzheimer's brain, CSF and plasma. Bulletin of Mathematical Biology. 2002

    2002

  9. [9]

    and Karran, E

    De Strooper, B. and Karran, E. The Cellular Phase of Alzheimer's Disease. Cell. 2016

    2016

  10. [10]

    Ciuperca, I. S. and Dumont, M. and Lakmeche, A. and Mazzocco, P. and Pujo-Menjouet, L. and Rezaei, H. and Tine, L. Alzheimer's disease and prion: an in vitro mathematical model. Discrete and Continuous Dynamical Systems—Series B. 2019

    2019

  11. [11]

    Erkkinen, M. G. and Kim, M. O. and Geschwind, M. D. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology. 2018

    2018

  12. [12]

    Greer, M. L. and Pujo-Menjouet, L. and Webb, G. F. A mathematical analysis of the dynamics of prion proliferation. Journal of Theoretical Biology. 2006

    2006

  13. [13]

    Hardy, J. A. and Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992

    1992

  14. [14]

    and Selkoe, D

    Hardy, J. and Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002

    2002

  15. [15]

    and Edskes, H

    Hall, D. and Edskes, H. Silent prions lying in wait: a two-hit model of prion/amyloid formation and infection. Journal of Molecular Biology. 2004

    2004

  16. [16]

    and Cr \'e peau, E

    Helal, M. and Cr \'e peau, E. and Pouchol, M. A. Alzheimer's disease: analysis of a mathematical model incorporating the role of prions. Journal of Mathematical Biology. 2014

    2014

  17. [17]

    and Lakmeche, A

    Helal, M. and Lakmeche, A. and Mazzocco, P. and Pujo-Menjouet, L. Stability analysis of a steady state of a model describing Alzheimer's disease and interactions with prion proteins. Journal of Mathematical Biology. 2019

    2019

  18. [18]

    The case for rejecting the amyloid cascade hypothesis

    Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nature Neuroscience. 2015

    2015

  19. [19]

    and Mishra, A

    Hussain, M. and Mishra, A. Advancements in understanding and addressing Alzheimer's disease: a comprehensive review. International Journal of Research in Medical Sciences. 2024

    2024

  20. [20]

    Jack, C. R. and Bennett, D. A. and Blennow, K. and Carrillo, M. C. and Dunn, B. and Haeberlein, S. B. and others. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology. 2013

    2013

  21. [21]

    Khan, H. T. A. and Addo, K. M. and Findlay, H. Public health challenges and responses to the growing ageing populations. Public Health Challenges. 2024

    2024

  22. [22]

    and Gimbel, D

    Laur \'e n, J. and Gimbel, D. A. and Nygaard, H. B. and Gilbert, J. W. and Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid- oligomers. Nature. 2009

    2009

  23. [23]

    Masters, C. L. and Bateman, S. and Blennow, K. and Rowe, C. M. and Sperling, R. A. and Morris, J. C. Alzheimer's disease. Nature Reviews Disease Primers. 2015

    2015

  24. [24]

    and Smith, H

    Mischaikow, K. and Smith, H. L. and Thieme, H. R. Asymptotically autonomous semiflows: chain recurrence and Lyapunov functions. Transactions of the American Mathematical Society. 1995

    1995

  25. [25]

    Moussa, C. E. and Brito, R. J. and Santos, A. G. and Pujol, M. A. and G \'o mez, M. S. Bispecific antibodies targeting A and PrP ^ C for Alzheimer's disease therapy. Molecular Neurodegeneration. 2021

    2021

  26. [26]

    Muldowney, J. S. Compound matrices and ordinary differential equations. Rocky Mountain Journal of Mathematics. 1990

    1990

  27. [27]

    and Vos, T

    Nichols, E. and Vos, T. and Hailu, S. B. S. and Snider, C. K. E. and Flaxman, A. D. and Roth, G. A. and others. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2019

    1990

  28. [28]

    and Arino, J

    Portet, S. and Arino, J. An in vivo intermediate filament assembly model. Mathematical Biosciences and Engineering. 2009

    2009

  29. [29]

    and Pujo-Menjouet, L

    Pr \"u ss, J. and Pujo-Menjouet, L. and Webb, G. F. and Zacher, R. Analysis of a model for the dynamics of prions. Discrete and Continuous Dynamical Systems—Series B. 2006

    2006

  30. [30]

    Selkoe, D. J. and Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016

    2016

  31. [31]

    Sims, J. R. and Donnelly, N. C. and Horn, S. A. C. and Arnold, A. M. S. and Cohen, T. S. and van Dyck, C. H. and others. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. Journal of the American Medical Association. 2023

    2023

  32. [32]

    Smith, H. L. Monotone Dynamical Systems: An Introduction to the Theory of Competitive and Cooperative Systems. 1995

    1995

  33. [33]

    Stelzmann, R. A. and Schnitzlein, H. N. and Murtagh, F. R. An English translation of Alzheimer's 1907 paper, `` \"U ber eine eigenartige Erkrankung der Hirnrinde''. Clinical Anatomy. 1995

    1907

  34. [34]

    and Swanson, S

    van Dyck, C.H. and Swanson, S. S. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and others. Lecanemab in early Alzheimer's disease. New England Journal of Medicine. 2023

    2023